Intratumoral macrophage phenotype and CD8<sup>+</sup> T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma
Lung Cancer , Volume 88 - Issue 3 p. 332- 337
Objectives: In patients with malignant pleural mesothelioma (MPM), local tumor outgrowth (LTO) after invasive procedures is a well-known complication. Currently, no biomarker is available to predict the occurrence of LTO. This study aims to investigate whether the tumor macrophage infiltration and phenotype of and/or the infiltration of CD8+ T-cells predicts LTO.
Materials and methods: Ten mesothelioma patients who developed LTO were clinically and pathologically matched with 10 non-LTO mesothelioma patients. Immunohistochemistry was performed on diagnostic biopsies to determine the total TAM (CD68), the M2 TAM (CD163) and CD8+ T-cell count (CD8).
Results: The mean M2/total TAM ratio differed between the two groups: 0.90±0.09 in the LTO group versus 0.63±0.09 in patients without LTO (p<0.001). In addition, the mean CD8+ T-cell count was significantly different between the two groups: 30 per 0.025cm2 (range 2-60) in the LTO group and 140 per 0.025cm2 (range 23-314) in the patients without LTO (p<0.01).
Conclusion: This study shows that patients who develop LTO after a local intervention have a higher M2/total TAM ratio and lower CD8+ cell count at diagnosis compared to patients who did not develop this outgrowth. We propose that the M2/total TAM ratio and the CD8+ T-cell amount are potential tools to predict which MPM patients are prone to develop LTO.
|Local tumor outgrowth, Macrophages, Mesothelioma, Prophylactic radiation of intervention tract, Tract metastases, Tumor micro-environment|
|Organisation||Department of Pulmonology|
Cornelissen, R, Lievense, L.A, Robertus, J.-L, Hendriks, R.W, Hoogsteden, H.C, Hegmans, J.P.J.J, & Aerts, J.G.J.V. (2015). Intratumoral macrophage phenotype and CD8+ T lymphocytes as potential tools to predict local tumor outgrowth at the intervention site in malignant pleural mesothelioma. Lung Cancer, 88(3), 332–337. doi:10.1016/j.lungcan.2015.03.013